EBOS Updates Market on Lapse of Performance Rights

EBOS Group Limited ( (AU:EBO) ) has issued an announcement.

EBOS Group Limited has announced that 7,878 performance rights granted under its equity incentive arrangements have lapsed. Following this change, the company now has 1,435,236 performance rights remaining on issue, slightly reducing potential future dilution for existing shareholders and refining the structure of its long‑term incentive pool.

The lapse of these rights suggests that certain performance or service conditions were not met, or that participants have exited the relevant schemes. While the adjustment is relatively small in scale, it provides updated transparency on EBOS’s capital instruments and may be of interest to investors tracking the company’s remuneration and equity‑based incentive structures.

The most recent analyst rating on (AU:EBO) stock is a Buy with a A$22.92 price target. To see the full list of analyst forecasts on EBOS Group Limited stock, see the AU:EBO Stock Forecast page.

More about EBOS Group Limited

EBOS Group Limited is a healthcare and pharmaceutical products company listed on the NZX and ASX. It operates across New Zealand and Australia, supplying medicines, medical devices, and related services to the healthcare and pharmacy sectors in both markets.

Average Trading Volume: 155,758

Technical Sentiment Signal: Sell

Current Market Cap: A$3.65B

For a thorough assessment of EBO stock, go to TipRanks’ Stock Analysis page.